Home » Newsletters » BioWorld Science

BioWorld Science

April 9, 2013

View Archived Issues

Novel small molecules useful as imaging tools in patients with cancer

Uncovering the antioxidative potential of paroxetine in hyperglycemic conditions

New CSF biomarker panel assay developed for the diagnosis of AD

Blood-based gene signature model for early detection of PD

Kowa and Daiichi Sankyo to end marketing partnership in Japan

AstraZeneca reports topline results from phase III fostamatinib study

Idenix Pharmaceuticals divulges novel agents for HCV infection

Canadian approval for Hologic's HPV assays

Emergent BioSolutions expands phase Ib study of TRU-016 with rituximab in CLL

ELOVL6 inhibitors suitable for treating insulin resistance

AC-708 described as CSF-1R inhibitor

Sanofi designs novel PKC-beta inhibitors

FDA approves Prolensa for postoperative inflammation and ocular pain

Ibrutinib receives third FDA breakthrough therapy designation

Roche and Isis Pharmaceuticals partner for Huntington's disease

Government of Japan, Gates Foundation and consortium of pharmaceutical companies launch partnership

Dainippon Sumitomo and Chugai agree to terminate joint development of anticancer vaccine candidates

Theratechnologies and Ferrer end tesamorelin agreement

Spectrum Pharmaceuticals commences phase II study of treatment for chemotherapy-induced neutropenia

Roche presents new aldosterone synthase inhibitors

DiaMedica cleared to conduct trial of lead diabetes treatment candidate

Anacor and Gates Foundation sign research agreement for neglected disease research

FDA approves Diclegis for morning sickness

Proximagen prepares new SSAO inhibitors

Glenmark Pharmaceuticals patents new MPGES-1 inhibitors

Crown Bioscience and Horizon Discovery sign new collaboration agreement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...